Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 9943 results found since Jan 2013.
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
DISCUSSION: This trial will help define the best neoadjuvant treatment sequence for borderline resectable PDAC and aims to evaluate if a total neoadjuvant treatment integrating iHD-SBRT improves the patients' oncological outcomes.TRIAL REGISTRATION: The study was registered at ClinicalTrails.gov (NCT05083247) on October 19th, 2021, and in the Clinical Trials Information System (CTIS) EU CT database (2022-501181-22-01) on July 2022.PMID:37735634 | DOI:10.1186/s12885-023-11327-x
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Christelle Bouchart Julie Navez Ivan Borbath Karen Geboes Timon Vandamme Jean Closset Luigi Moretti Pieter Demetter Marianne Paesmans Jean-Luc Van Laethem Source Type: research
PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-kB signaling in patients with pancreatic cancer
CONCLUSIONS: Cytotoxic T cells in the blood of PDAC patients remain sensitive to reinvigoration by PD-1 blockade and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to anti-tumor immunity.PMID:37733830 | DOI:10.1158/1078-0432.CCR-23-1444
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Lestat R Ali Patrick J Lenehan Victoire Cardot-Ruffino Andressa Dias Costa Matthew H G Katz Todd W Bauer Jonathan A Nowak Brian M Wolpin Thomas A Abrams Anuj Patel Thomas E Clancy Jiping Wang Joseph D Mancias Matthew J Reilley Chee-Chee H Stucky Tanios S Source Type: research
Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer
CONCLUSION: NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.PMID:37733788 | DOI:10.1158/1078-0432.CCR-23-1593
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Xu Cao Kristen E Muller Mary D Chamberlin Jiang Gui Peter A Kaufman Gary N Schwartz Roberta M DiFlorio-Alexander Brian W Pogue Keith D Paulsen Shudong Jiang Source Type: research
Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer
CONCLUSION: This study has shown significance in reducing LD measurements on ultrasound as a predictor of PCR and RCB class. This adds weight to the current practice of using ultrasound at the start, mid and end of chemotherapy cycles to monitor NACT responses.PMID:37734976 | DOI:10.1016/j.crad.2023.07.010
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: H F Lim A Sharma C Gallagher P Hall Source Type: research
Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer
CONCLUSION: NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.PMID:37733788 | DOI:10.1158/1078-0432.CCR-23-1593
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xu Cao Kristen E Muller Mary D Chamberlin Jiang Gui Peter A Kaufman Gary N Schwartz Roberta M DiFlorio-Alexander Brian W Pogue Keith D Paulsen Shudong Jiang Source Type: research
Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer
CONCLUSION: This study has shown significance in reducing LD measurements on ultrasound as a predictor of PCR and RCB class. This adds weight to the current practice of using ultrasound at the start, mid and end of chemotherapy cycles to monitor NACT responses.PMID:37734976 | DOI:10.1016/j.crad.2023.07.010
Source: Clinical Genitourinary Cancer - September 21, 2023 Category: Cancer & Oncology Authors: H F Lim A Sharma C Gallagher P Hall Source Type: research
Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer
CONCLUSION: NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.PMID:37733788 | DOI:10.1158/1078-0432.CCR-23-1593
Source: Clinical Genitourinary Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xu Cao Kristen E Muller Mary D Chamberlin Jiang Gui Peter A Kaufman Gary N Schwartz Roberta M DiFlorio-Alexander Brian W Pogue Keith D Paulsen Shudong Jiang Source Type: research
PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-kB signaling in patients with pancreatic cancer
CONCLUSIONS: Cytotoxic T cells in the blood of PDAC patients remain sensitive to reinvigoration by PD-1 blockade and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to anti-tumor immunity.PMID:37733830 | DOI:10.1158/1078-0432.CCR-23-1444
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Lestat R Ali Patrick J Lenehan Victoire Cardot-Ruffino Andressa Dias Costa Matthew H G Katz Todd W Bauer Jonathan A Nowak Brian M Wolpin Thomas A Abrams Anuj Patel Thomas E Clancy Jiping Wang Joseph D Mancias Matthew J Reilley Chee-Chee H Stucky Tanios S Source Type: research
Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer
CONCLUSION: Partial boost RT in MIBC is associated with good local disease control and high rates of cystectomy free survival. We observed a pattern of predominantly LR in the tumor bed, supporting the use of a dose-painted approach/de-escalation strategy to the uninvolved bladder. Prospective trials are required to compare oncological and toxicity outcomes between dose-painted and homogeneous bladder RT techniques.PMID:37730609 | DOI:10.1186/s13014-023-02338-w
Source: Cancer Control - September 20, 2023 Category: Cancer & Oncology Authors: Inmaculada Navarro-Domenech Shinthujah Arulanantham Zhihui Amy Liu Michael Tjong Vickie Kong Victor Malkov Tony Tadic Neil Fleshner Girish Kulkarni Alexandre R Zlotta Charles Catton Alejandro Berlin Srikala Sridhar Di Maria Jiang Peter Chung Srinivas Rama Source Type: research
Pre-operative Neo-adjuvant Chemotherapy Related miRNAs as Key Regulators and Therapeutic Targets in Colorectal Cancer
CONCLUSION: In patients with colorectal cancer, miRNA expression in the tumoral regions before and after neoadjuvant therapy has represented a variable pattern. It has been shown that miRNA studies can be used to predict the clinical course and response to treatment with differences in expression levels. It has been concluded that specific miRNAs may be candidate biomarkers for colorectal cancer.PMID:37723961 | DOI:10.2174/1874609816666230816152744
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Orcun Yalav Ozge Sonmezler Kivilcim Eren Erdogan Ahmet Rencuzogullari Figen Doran Atil Bisgin Ibrahim Boga Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
Neoadjuvant chemotherapy for advanced colonic cancer: standard of care or is the jury still out?
Br J Surg. 2023 Sep 19:znad281. doi: 10.1093/bjs/znad281. Online ahead of print.NO ABSTRACTPMID:37724780 | DOI:10.1093/bjs/znad281
Source: The British Journal of Surgery - September 19, 2023 Category: Surgery Authors: Peter G Vaughan-Shaw Martyn D Evans Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
